Introduction
Mitogen-activated protein kinase (MAPK) signalling is defined by its modular organization within an interwoven network of MAPKs, MAPK kinases (MKKs) and MAPKK kinases (MAP3Ks) [1] . Most biologically relevant extracellular stimuli activate several of these pathways leading to complex signalling events, which translate into distinct physiological responses. Pathogen-associated molecular patterns, including LPS, activate all three major MAPK pathways -ERK1/2, p38 MAPK and JNK cascades in the cells of the innate immune system, contributing significantly to the inflammatory response. The key role of p38 MAPK in inflammation is underlined by the fact that p38 MAPK α/β were originally identified as 'cytokine-suppressor anti-inflammatory drug-binding proteins', the targets of the pyridinyl imidazole compounds, such as SB203580, which inhibited pro-inflammatory cytokine production by myeloid cells [2] . Research in the past decades using knockout models and novel, highly specific kinase inhibitors have unravelled the complexity of MAPK signalling with non-linear cross-talks, feedforward and feedback regulatory loops. This has generated great interest in the dissection of these pathways with a view to identifying targetable nodes with therapeutic benefits in the treatment of chronic inflammation [3] . p38 MAPK are crucial mediators of inflammatory signalling. There are four p38 MAPK isoforms encoded by the mammalian genome denoted as p38 MAPK α, β, γ and δ. Of these, the ubiquitously expressed p38 MAPK α is the major regulator of inflammation. While p38 MAPK α was initially regarded as a suitable target in the treatment of chronic inflammation, the embryonic lethality associated with the p38
MAPK α KO mouse model as well as inhibitor toxicity and side effects in clinical trials revealed a possible role for this kinase in basic cellular processes, including development. Interestingly, conditional deletion of p38 MAPK α in adult mice led to increased susceptibility to tumourigenesis due to a hyperactivation of JNK signalling, suggesting a role for this kinase in a negative feedback loop directed to control TGFβ-activated protein kinase-1 (TAK1) activity via TAK1-binding protein 1 (TAB1) phosphorylation. This finding made it a less attractive direct target for anti-inflammatory therapy [4] [5] [6] and led to the extension of the search for additional druggable kinases in the cascade. MAPK-activated protein kinase-2 attracted much interest [3] as it is the strongest downstream mediator of the pro-inflammatory functions of p38 MAPK α/β.
The TAK1-MKK3/6 axis in p38 MAPK activation MAPK signalling follows a funnelling scheme with a large number of upstream MAP3K and MAP2Ks responding to diverse extracellular cues, converging the signals to fewer MAPKs, activating transcription factors and other effector molecules with much redundancy. All of the three major mammalian MAPKs -ERK1/2, p38 MAPK and JNK are activated by more than one upstream MAP2K. ERK1/2 are exclusively activated by MKK1/MKK2 and JNKs are activated by MKK4/MKK7. The p38
MAPK family lies at the crossroads with MKK3/MKK6 being the major activators of the pathway and, in addition with MKK4, contributing to p38 dual phosphorylation in response to certain stimuli [1, 7] . While there are more than half a dozen MAP3Ks capable of activating the p38 MAPK signalling in response to diverse stimuli, TAK1/MAP3K7 is responsible for activating the MKK3/MKK6-p38 pathway in response to Toll-like receptor (TLR)/IL-1 receptor activation. In addition to its role as an MAP3K, TAK1 also acts as an activating kinase for the IκB kinase (IKK) complex downstream to the TNF-receptor and the TLR/IL-receptors [8] .
The activation of TAK1 and downstream IKK and MKK3/6 activation in LPS-stimulated macrophages is dependent on TAK1-binding proteins 1/2 (TAB1 and TAB2) [9] . Interestingly, p38
MAPK α exerts a negative feedback control on TAK1 activity by phosphorylating TAB1 [4] . In addition, TAB1-binding to p38
MAPK can lead to auto-phosphorylation and activation of p38 MAPK α in a TAK1-MKK3/6-independent manner in response to stimuli, such as osmotic and ribotoxic stress [10, 11] . The involvement of TAK1 in LPS-induced p38
MAPK activation is also cell type-specific. While LPS-stimulated p38 MAPK activation was almost completely abrogated in TAK1-KO MEFs, it was only marginally altered in TAK1-KO macrophages. Moreover, TAK1-KO neutrophils showed enhanced activation of p38 MAPK and IKKs, indicating that TAK1 is a negative regulator of inflammation in neutrophils [12] . Consistently, TAK1 deletion leads to spontaneous apoptosis and TNF sensitivity in epithelial cells [13] , and thymocytes [14] , while the myeloid-specific KO developed myelomonocytic leukaemia [15] . Cell type-specific differences in the composition of the TAK1-TAB complexes could be attributed to these marked differences in its role in the regulation of inflammation [16] .
The TPL2-MKK1/2-ERK1/2 axis
In contrast with TAK1, which acts as a signalling hub activating IKKs and a panel of MAP2Ks, TPL2 was described as a rather specific MAP3K with very well defined bias towards the MKK1/2-ERK1/2 pathway (reviewed in ref. [17] ). The role of TPL2 in the pro-inflammatory cytokine production was established very early on, but no consensus regarding the responsible mechanisms has been reached to date [18] . While initial studies reported that TPL2 played a role in the ARE-dependent post-transcriptional control of TNFα biosynthesis, later studies identified a role for ERK1/2-dependent phosphorylation of TNFα-converting enzyme in the processing and cell surface expression of TNFα in response to LPS [19] . The unique monogamy of TPL2 with MKK1/2-ERK1/2 signalling appears to coincide with the unique mode of its activation. Cytosolic pools of TPL2 exist in complex with the NfκB-p105 protein and the ubiquitin-binding factor ABIN2. While inside this complex, TPL2 is locked in its inactive form. TLR/IL-1R-dependent activation of IKKs is mediated by TAK1 and leads to the phosphorylation-dependent ubiquitination and proteasomal degradation of NfκB-p105, releasing TPL2 and causing its activation and subsequent downstream MKK-ERK signalling [20, 21] . IKK2 is also involved in the direct phosphorylation of TPL2 at S400, stimulating its activity as MKK [22] . Interestingly, genetic deletion of ABIN2 or p105, significantly reduces the steady-state levels of TPL2, leading to diminished ERK signalling [21, 23] . Unexpectedly, deletion of p38 MAPK γ,δ also reduces the steady-state levels of TPL2 and ABIN2 in macrophages, indicating that these isoforms of p38MAPK may phosphorylate and stabilize components of the TPL2-containing protein complex [24] . Previous studies comparing the TPL2 KO (Map3k8 −/− ) and non-phosphorylatable p105 knockin mice (Nfkb1 SSAA ) presented an unexpected evidence that the regulation of TNFα production by TPL2 is independent of its role in ERK1/2 activation [20] .
TPL2 as a novel upstream kinase for MKK3/6
In the recent issue of the Biochemical Journal, Pattison et al. [25] utilized a catalytic-dead TPL2 (Map3k8 D270A/ D270A ) knockin model [26] to screen for novel substrates of TPL2 in LPS-stimulated macrophages by phosphoproteomics. To identify novel substrates independent of ERK1/2 and relevant to TNFα production, this dataset was compared with LPS-stimulated phosphosites sensitive to a MKK1/2 inhibitor -PD0325901 in wild-type macrophages. Apart from numerous phosphorylations found to be both TPL2-and ERK1/2-dependent, they were able to identify 18 TPL2-dependent, but ERK1/2-independent phosphosites of 15 different proteins. Some of these phosphosites belonged to the known direct TPL2 targets p105 NFκB1 and MEK1, but they also detected a regulatory phosphosite of MKK3/6, indicating a direct phosphorylation of these MAP2Ks by TPL2 and a subsequent activation of p38 MAPK in LPS-stimulated macrophages. Indeed, recombinant MKK6 and peptides spanning the MKK3/6 phosphorylation sites were directly phosphorylated by TPL2 in vitro [25, 27] and LPS-induced p38 MAPK α activity (as detected by activation loop phosphorylation) was reduced, but not diminished in Map3k8 D270A/D270A macrophages [25] . Pattison et al. speculate that the remaining LPS-stimulated activation of p38
MAPK α is probably due to MKK4, which is a direct target of TAK1. Consequently, they analyzed TNF signalling, a process where MKK3/6 are the predominantly activated MAP3Ks that mediate p38MAPK activation [7] . As expected, TNF-induced activation of p38 MAPK α is almost completely abrogated in Map3k8 D270A/D270A macrophages. By demonstrating that phosphorylation of NFκB1 p105 was necessary for TPL2-dependent MKK3/6 activation, Pattison et al. have established a new signalling pathway from TAK1 to p38MAPK via IKK, p105 NFκB1 and TPL2.
Interestingly, a recent publication has revealed that p38 MAPK γ/δ, which are also activated by MKK3/6, are essential for maintaining a functional steady-state level of TPL2 [24] . Together with this observation, the newly identified signalling connection between TPL2 and MKK3/6 forms a positive feedback loop in inflammatory signalling, where TPL2 via MKK3/6 stimulates p38 MAPK γ/δ activity which in turn stabilizes active TPL2 levels ( Figure 1, red loop) . The interplay of the known negative feedback regulation from p38 MAPK α to the TAB/ TAK1 complex (Figure 1 , green loops) and this new feed-forward loop adds further complexity to our [25] in the recent issue of the Biochemical Journal, combined with recent results showing the role of p38MAPKγ/δ isoforms in stabilizing the functional steady-state levels of TPL2 and ABIN2, probably by direct phosphorylation of subunits of the TPL2/p105/ABIN2 complex [24] , unravels a novel feed-forward loop in TLR signalling (in red). The already established negative feedback control exerted by p38MAPKα on TAK1 by phosphorylating TAB1 is shown in green.
understanding of the regulation of inflammation. Nevertheless, targeting positive regulators in a feed-forward loop seems a more logical approach than to target components involved in negative feedback controls, such as p38 MAPK α/β. Since it has been established that TPL2 is situated at a critical node in the regulation of inflammation, it has to be considered a promising target in the search for ways to successfully interfere with the onset and course of inflammation.
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